title: Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis.
abstract: Decitabine has been approved for the treatment of all subtypes of myelodysplastic syndrome (MDS). However, the optimal regimen for decitabine treatment is not well established. In this study, an observational, retrospective and multi-center analysis was performed to explore the decitabine schedule for the treatment of MDS. A total of 79 patients received reduced dosage decitabine treatment (15 mg/M2/day intravenously for five consecutive days every four weeks). Fifty-three out of the 79 patients were defined as intermediate-2/high risk by international prognostic scoring system (IPSS) risk category. 67.1% of MDS patients achieved treatment response including complete response (CR) (n = 23), Partial response (n = 1), marrow CR (mCR) with hematological improvement (HI) (n = 11), mCR without HI (n = 11) and HI alone (n = 7) with a median of 4 courses (range 1-11). The median overall survival (OS) was 18.0 months. The median OS was 22.0, 17.0 and 12.0 months in the patients with CR, those with other response, and those without response, respectively. In addition, this regimen contributed to zero therapy-related death and punctual course delivery, although III or IV grade of cytopenia was frequently observed. In conclusion, the 15 mg/M2/d×5 day decitabine regimen was effective and safe for Chinese MDS patients with IPSS score of 0.5 or higher.
authors.affiliation: Department of Hematology, the Sixth People's Hospital affiliated with Shanghai Jiaotong University, Shanghai, China.
authors.forename: Xiao
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Hematology, Qilu Hospital affiliated with Shandong University, Jinan, China.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Song
authors.affiliation: Department of Hematology, Ruijin Hospital affiliated with Shanghai Jiaotong University School of Medicine, Shanghai, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Department of Hematology, the Sixth People's Hospital affiliated with Shanghai Jiaotong University, Shanghai, China.
authors.forename: Chunkang
authors.initials: C
authors.lastname: Chang
authors.affiliation: Department of Hematology, the Sixth People's Hospital affiliated with Shanghai Jiaotong University, Shanghai, China.
authors.forename: Dong
authors.initials: D
authors.lastname: Wu
authors.affiliation: Department of Hematology, the Sixth People's Hospital affiliated with Shanghai Jiaotong University, Shanghai, China.
authors.forename: Lingyun
authors.initials: L
authors.lastname: Wu
authors.affiliation: Department of Hematology, the Sixth People's Hospital affiliated with Shanghai Jiaotong University, Shanghai, China.
authors.forename: Jiying
authors.initials: J
authors.lastname: Su
authors.affiliation: Department of Hematology, the Sixth People's Hospital affiliated with Shanghai Jiaotong University, Shanghai, China.
authors.forename: Xi
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Hematology, the Sixth People's Hospital affiliated with Shanghai Jiaotong University, Shanghai, China.
authors.forename: Liyu
authors.initials: L
authors.lastname: Zhou
authors.affiliation: Department of Hematology, the Sixth People's Hospital affiliated with Shanghai Jiaotong University, Shanghai, China.
authors.forename: Luxi
authors.initials: L
authors.lastname: Song
authors.affiliation: Department of Hematology, the Sixth People's Hospital affiliated with Shanghai Jiaotong University, Shanghai, China.
authors.forename: Zheng
authors.initials: Z
authors.lastname: Zhang
authors.affiliation: Department of Hematology, the Sixth People's Hospital affiliated with Shanghai Jiaotong University, Shanghai, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Xu
authors.affiliation: Department of Hematology, Qilu Hospital affiliated with Shandong University, Jinan, China.
authors.forename: Ming
authors.initials: M
authors.lastname: Hou
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D044466:Asian People; D001374:Azacitidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D002681:China; D050762:Cyclin-Dependent Kinase Inhibitor p15 / Q000378:metabolism; D000077209:Decitabine; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D050762:Cyclin-Dependent Kinase Inhibitor p15; D000077209:Decitabine; D001374:Azacitidine
references.citation: Br J Haematol. 1976 Aug;33(4):451-8
references.pmid: 188440
references.citation: Ann Hematol. 2011 Jun;90(6):643-53
references.pmid: 21125401
references.citation: Cancer. 2006 Apr 15;106(8):1794-803
references.pmid: 16532500
references.citation: Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Feb;21(1):121-5
references.pmid: 23484704
references.citation: J Clin Oncol. 2013 Jul 10;31(20):2548-53
references.pmid: 23733767
references.citation: Blood. 2007 Aug 1;110(3):1082-3; author reply 1083
references.pmid: 17644750
references.citation: Adv Cancer Res. 1998;72:141-96
references.pmid: 9338076
references.citation: Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):131-8
references.pmid: 23260600
references.citation: Cancer Res. 2006 May 15;66(10):5495-503
references.pmid: 16707479
references.citation: Haematologica. 2011 Oct;96(10):1441-7
references.pmid: 21659363
references.citation: Cancer Res. 2005 Aug 15;65(16):7086-90
references.pmid: 16103056
references.citation: Leuk Lymphoma. 2010 Dec;51(12):2250-7
references.pmid: 20929328
references.citation: Blood. 2006 Sep 1;108(5):1497-503
references.pmid: 16675707
references.citation: Blood. 2007 Jan 1;109(1):52-7
references.pmid: 16882708
references.citation: Cancer Sci. 2012 Oct;103(10):1839-47
references.pmid: 22816487
references.citation: Blood. 2004 Mar 1;103(5):1635-40
references.pmid: 14604977
references.citation: Semin Cancer Biol. 1999 Oct;9(5):359-67
references.pmid: 10547344
references.citation: J Clin Oncol. 2011 May 20;29(15):1987-96
references.pmid: 21483003
references.citation: J Clin Oncol. 2009 Aug 10;27(23):3842-8
references.pmid: 19528372
references.citation: Semin Radiat Oncol. 2003 Jul;13(3):176-81
references.pmid: 12903007
references.citation: Blood. 1997 Mar 15;89(6):2079-88
references.pmid: 9058730
references.citation: Ther Clin Risk Manag. 2007 Oct;3(5):807-17
references.pmid: 18473005